Intrexon   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Blacksburg VA United States (1998)

Organization Overview

First Clinical Trial
2011
NCT00968760
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Intrexon Corporation | Intrexon T1D Partners, LLC | PGEN Therapeutics, Inc., a subsidiary of Precigen, Inc. | Precigen, Inc | Xogenex, LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Cardiovascular Diseases (Phase 1)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Epidermolysis Bullosa (Phase 2)

Epidermolysis Bullosa Dystrophica (Phase 2)

Fallopian Tube Neoplasms (Phase 1)

Heart Failure (Phase 1)

Leukemia (Phase 1)

Leukemia, Biphenotypic, Acute (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Neoplasm, Residual (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 1)

Peritoneal Neoplasms (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Preleukemia (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 24
  • # of Trial APIs: 27